6972172618 16:18 From: RS Woodson C. Merrell M Webfax Page: 1713 FAX COVER SHEET To: Jeffrey Epstein / mz From: Lisa Woodson Merrell MD PLLC Company; ————_—_—_—____— Company: Date: 9/21/2018 Pages wicover: 13 Subject: 9-14-18 LABCORP Lab Results Jeff Comments: EFTA00299800

--=PAGE_BREAK=--

6972172618 16:18 Fron: i! “oodson C. Merrell M WVebfax Page: 2713 on . LabCorp Patient Report Specimen ID: 257-480-2371-0 Acct #: 31143092 Phone: ate: 6s Controf ID: F5B31143092 Woodson Merrell EPSTEIN, JEFFREY 44 E 67th St 9E7ISTST New York NY 10065 NEW YORK NY 10021 eee eee halt Patient Details Specimen Details Physician Details DOB: 01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRELL Agely/m/d): 065/07/25 Date received: 09/15/2018 Referring: Gender: M SSN: Dateentered: 09/15/2018 ID: MERRELL Patient ID: 7 Date reported: 09/20/2018 0832 ET NPI: 1023153509 General Comments & Additional information Total Volume: Not Provided Fasting: No Ordered items CBC With Differential/Piatelet; Comp. Metabolic Panel (14); Urinalysis, Routine; PE+Interp(Rfx IF E),S; Lipid Panel; iron and TIBC; Testosterone,Free+Weakly Bound; Vitamin B12 and Folate; FSH and LH; C-Reactive Protein, Cardiac; Hemoglobin A‘c; Prostate-Spacific Ag, Serum; TSH; Vitamin 0, 25-Hydroxy; Lipoprotein (a); IGF-1; ANA wiReflex; Homocyst(e)ine, Plasma; Prolactin; Thyroxine (T4) Free, Direct, S; Cortisol; DHEA-Sulfate; Estradiol; Uric Acid; Phosphorus; LDH; GGT; Amylase; Ferritin, Serum; Insulin; Calcium, lonized, Serum; Fibrinogen Activity, Magnesium, RBC; Request Problem REFERENCE IN’ CBC With Differential/Plat WBC 5.7 x10E3/uL 3.4 - 10.8 o1 RBC 4.90 x10E6/uL 4.14 - 5.80 61 Hemoglobin 14.7 g/dL 13.0 - 17.7 o1 Hematocrit 42.2 % 37.5 - 51.0 o1 MCV 86 fL 79 - 97 01 MCH 30.0 pg 26.6 - 33.0 01 MCHC 34.8 g/dL 31.5 - 35.7 o1 RDW 14.6 $ 12.3 - 15.4 01 Platelets 242 x10E3/uL 150 - 379 01 Neutrophils 50 $ Not Estab. 01 Lymphs 37 + Not Estab. o1 Monocytes 5 % Not Estab. 01 Eos 7 % Not Estab o1 Basos 1 t Not Estab 01 Neutrophils (Absolute) 2.8 x10E3/uL 1.4 - 7.0 01 Lymphs (Absolute) 2.1 x10E3/uL 0.7 - 3.1 01 Monocytes (Absolute) 0.3 *x10B3/uL 0.21 - 0.9 01 Eos (Absolute) 0.4 x10E3/uL 0.0 - 0.4 01 Baso (Absolute) 0.0 x10B3/uL 0.0 - 0.2 01 Immature Granulocytes is) % Not Estab. 01 Immature Grans (Abs) 0.0 x10E3/uL 0.0 - 0.1 01 Comp. Metabolic Panel (14) Glucose 128 High mg/dL 65 - 99 o1 Sample is lipemic. This may cause spurious increases in TBili, DBili, AST, ALT, and UIBC (if ordered). Clinical correlation indicated. Specimen received hemolyzed. Clinical correlation indicated. RT RO EAA IETS LE A ST CO LS TET TI: | eee Date issued: 09/20/18 0832 ET FINAL REPORT Page 1 of 6 This document contains private and confidential i ie tected by state and federal law. ® 1995-2018 Laboratory Corporation of America® Holdings if you have received this document in error, please call All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299801

--=PAGE_BREAK=--

6972172618 16:18 Fron: Si Yoodson C. Merrell M Webfax Page: 3713 % : = Patient Report Patient: EPSTEIN, JEFFREY Specimen ID: 257-480-2371-0 DOB: 01/20/1953 Patient ID: Control ID: F5B31143092 Date collected: 09/14/2018 1255 Local RESULT REFERENCE IN BUN 22 mg/dL 8 - 27 01 Creatinine 0.96 mg/dL 0.76 - 1.27 01 eGFR If NonAfricn Am 83 mL/min/1.73 >59 eGFR If Africn Am 95 mL/min/1.73 >59 BUN/Creatinine Ratio 23 10 - 24 Sodium 138 mmol/L 134 - 144 o1 Potassium 4.2 mmol/L 3.5 ~ 5.2 01 Sample is lipemic. This may cause spurious increases in TBili, DBili, AST, ALT, and UIBC (if ordered). Clinical correlation indicated. Specimen received hemolyzed. Clinical correlation indicated. Chloride 102 mmol/L 96 ~- 106 01 Carbon Dioxide, Total 20 mmol/L 20 - 29 OL Calcium 9.4 mg/dL 8.6 - 10.2 OL Protein, Total 6.7 g/dL 6.0 - 8.5 o1 Albumin 4.3 g/dL 3.6 - 4.8 01 Globulin, Total 2.4 g/dL 1.5 - 4.5 A/G Ratio 1.8 1.2 - 2.2 Bilirubin, Total 0.3 mg/dL 0.0 - 1.2 o1 Alkaline Phosphatase 71 IU/L 39 - 117 O1 AST (SGOT) 26 IU/L 0 - 40 o1 The specimen was lipemic. The lipemia was cleared by ultracentrifugation before testing. However HDL, direct LDL, cholesterol and triglyceride (if ordered) were performed prior to ultracentrifugation. ALT (SGPT) 37 Iu/L 0 - 44 01 Urinalysis, Routine Urinalysis Gross Exam 01 Specific Gravity 1.027 1.005 - 1.030 01 pH 5.5 5.0 - 7.5 o1 Urine-Color Yellow Yellow o1 Appearance Clear Clear 01 WBC Esterase Negative Negative 01 Protein Negative Negative/Trace 01 Glucose Negative Negative ol Ketones Negative Negative 01 Occult Blood Negative Negative o1 Bilirubin Negative Negative 01 Urobilinogen, Semi-Qn 0.2 EU/dL 0.2 - 1.0 OL Nitrite, Urine Negative Negative ol Microscopic Examination Microscopic follows if indicated. 01 PE+Interp(Rfx IFE),S EE RE ES LRT TT ETE A LE SR TST RSA PRA A UES RR RR A Date Issued: 09/20/18 0832 ET FINAL REPORT Page 2 of 6 This document contains private and confidential health information protected by state and federal lav. ‘© 1995-2018 Laboratory Corporation of America® Holdings If you have received this document in error, please le All Rights Reserved - Enterprise Report Version: 1,00 EFTA00299802

--=PAGE_BREAK=--

6972172618 16:18 Fron: Se Yoodson C. Merrell M Webfax Page: 4713 Patient: EPSTEIN, JEFFREY Specimen 10: 257-480-2371-0 008: 01/20/1953 Patient ID: Control ID: FS831 143092 Date collected: 09/14/2018 1255 Local RESULT UNITS Albumin 4.0 g/dL 2.9 - 4.4 01 Alpha-1-Globulin 0.1 g/dL 0.0 - 0.4 01 Alpha-2-Globulin 0.8 g/dL 0.4 - 1.0 01 Beta Globulin 0.9 g/dL 0.7 ~ 1.3 01 Gamma Globulin 0.9 g/dL 0.4 - 1.8 01 M-Spike Not Observed g/dL Not Observed 01 Globulin, Total 2.7 g/dL 2.2 - 3.9 A/G Ratio 1.5 0.7 - 1.7 Please note: 01 Protein electrophoresis scan will follow via computer, mail, or courier delivery. Interpretation({See Below) o1 The SPE pattern appears essentially unremarkable. Evidence of monoclonal protein is not apparent. PDP . o1 Lipid Panel Cholesterol, Total 234 High mg/dL 100 - 199 01 Triglycerides 1714 Alert mg/dL 0 - 149 01 Results confirmed on dilution. HDL Cholesterol 19 Low mg/dL >39 01 VLDL Cholesterol Cal mg/dL 5 - 40 The calculation for the VLDL cholesterol is not valid when triglyceride level is >400 mg/dL. LDL Cholesterol Calc mg/dL 0 - 99 Triglyceride result indicated is too high for an accurate LDL cholesterol estimation. Iron and TIBC Iron Bind.Cap. (TIBC) 320 ug/dL 250 ~ 450 UIBC 252 ug/di lll - 343 OL Tron 68 ug/dL 38 - 169 o1 Tron Saturation 21 $ 15 - 55 Testosterone, Free+Weakly Bound Testosterone, Serum 140 Low ng/db 264 - 916 01 Adult male reference interval is based on a population of healthy nonobese males (BMI <30) between 19 and 39 years old. Travison, et.al. JCEM 2017,102;1161-1173. PMID: 28324103. Testost., % Free+Weakly Bound 9.0 - 46,0 02 Test Not Performed. Specimen is lipemic. Testost., FiW Bound 40.0 - 250.0 Unable to calculate result since non-numeric result obtained for component test. Vitamin B12 and Folate SE A 2 EA TE A RE 5 LAR A OT ES SRC A PPE, Date sued: 09/20/18 0832 ET FINAL REPORT Page 3 of 6 This document contains private and confidential healt! rotected by state and federal law. © 1995-2018 Laboratory Comoration of America® Holdings Ifyou have received this document in error, please call Ali Rights Reserved - Enterprise Report Version: 1.00 EFTA00299803

--=PAGE_BREAK=--

6972172618 16:18 From: QR Woodson C. Merrell M Webfax Page: 5713 Patient: EPSTEIN, JEFFREY Specimen iD: 257-480-2371.0 DOB: 01/20/1953 Patient ID: Control ID: F5B31143092 Date collected: 09/14/2018 1255 Local Vitamin B12 463 pg/mL 232 - 1245 01 Folate (Folic Acid), Serum 4.4 ng/mL >3.0 01 Note: 01 A serum folate concentration of less than 3.1 ng/ml is considered to represent clinical deficiency. PSH and LH LH 3.7 mIU/mL 1.7 - 8.6 01 FSH 4.4 mIU/mL 1.5 - 12.4 o1 C-Reactive Protein, Cardiac 1.56 mg/L 0.00 - 3.00 01 Relative Risk for Future Cardiovascular Event Low <1.00 Average 1.00 - 3.00 High >3.00 Hemoglobin Alc Hemoglobin Alc 5.5 % 4.8 - 5.6 01 Please Note: 01 Prediabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0 Prostate-Specific Ag, Serum Prostate Specific Ag, Serum 0.7 ng/mL 0.0 - 4.0 01 Roche ECLIA methodology. According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines bicchemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease. TSE 1.290 ulU/mL 9.450 - 4.500 01 Vitamin D, 25-Hydroxy 20.2 Low ng/mL 30.0 - 100.0 01 Vitamin D deficiency has been defined by the Institute of Medicine and an Endocrine Society practice guideline as a level of serum 25-OH vitamin D less than 20 ng/mL (1,2). The Endocrine Society went on to further define vitamin D insufficiency as a level between 21 and 29 ng/mL (2). 1. IOM (Institute of Medicine). 2010. Dietary reference intakes for calcium and D. Washington DC: The National Academies Press. 2. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. JCEM. 2011 Jul; 96(7):1911-30. OT PSE RR ELIS TEL DMT AS ETP PE RE AS AL A EM PORE EP Date Issued: 09/20/18 0832 ET FINAL REPORT Page 4 of 6 This document contains private and canfidential health i . tected by state and federal law. ‘© 1995-2018 Laboratory Corporation of America® Holdings Ifyou have received this document in error, please call All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299804

--=PAGE_BREAK=--

6972172618 16:18 5 NO Patient: EPSTEIN, JEFFREY BOB: 01/20/1953 Patient ID: Control ID: F5831143092 Fron: ii Yoodson C. Merrell M Vebfax Page: 6/13 Specimen ID: 257-480-2371-0 REFERENCE IN Date collected: 09/14/2018 1255 Local Lipoprotein (a) 20 nmol/L <75 01 Note: Values greater than or equal to 75 nmol/L may indicate an independent risk factor for CHD, but must be evaluated with caution when applied to non-Caucasian populations due to the influence of genetic factors on Lp(a) across ethnicities. IGF-1 Insulin-Like Growth Factor I 137 ng/mL 49 - 188 02 ANA w/Reflex ANA Direct Negative Negative 01 Homocyst(e)ine, Plasma 14.9 umol/L 0.0 - 15.0 01 Prolactin 3.9 Low ng/mL 4.0 - 15.2 01 Thyroxine (T4) Free, Direct, $ T4, Free (Direct) 1.05 ng/dL 0.82 = 1.77 01 Cortisol 3.7 ug/dL 01 Cortisol AM 6.2 - 19.4 Cortisol PM 2.3 - 11.9 DHEA-Sulfate 181.8 ug/dL 30.9 - 295.6 01 Estradiol 28.3 pg/mL 7.6 - 42.6 01 Roche ECLIA methodology Uric Acid Uric Acid 6.8 mg/dL 3.7 - 8.6 01 Please Note: 01 Therapeutic target for gout patients: <6.0 Phosphorus 3.6 mg/dL 2.5 - 4.5 o1 LDE 213 Iu/L 121 - 224 01 GGT 25 IU/L 0 - 65 o1 Amylase 37 U/L 31 124 01 Ferritin, Serum 104 ng/mL 30 - 400 OL Insulin 47.2 High uIU/mL 2.6 - 24.9 01 Date Issued: 09/20/18 0832 ET FINAL REPORT Page 5 of 6 This document contains privete and confidential healt! " otected by state and federal law. © 1995-2018 Laboratory Corporation of America® Holdings Ifyou have received this document in error, please call All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299805

--=PAGE_BREAK=--

6972172618 16:18 From: @eRR@eeene YWoodson C. Merrell M Webfax Page: 7713 Lal orp es Patient: EPSTEIN, JEFFREY Specimen 1D: 257-480-2371-0 DOB: 01/20/1953 Patient ID: Control ID: F5831143092 Date collected: 09/14/2018 1255 Local UNITS REFERENC’ ‘ Ionized, Serum 5.3 ma/dL 4.5 - 5.6 01 Calcium, Fibrinogen Activity 330 mo/daL 193 - 507 01 Specimen was ultracentrifuged before testing to remove extreme lipemia. Results should be interpreted with caution. Magnesium, RBC 5.4 mg/dL 4.2 - 6.8 02 Plasma NOT separated from cells; may falsely decrease RBC Magnesium levels. Request Problem 02 Test Not Performed. Specimen is lipemic. TEST: 143257 Testost., % Pree+Weakly Bound Panel: 143255 “Of RN LabCompRartan 69 First Avenue, Raritan, NJ 08869-1800 02 =+BN LabCorp Burlington Dir: William F Hancock, MD 1447 York Court, Burlington, NC 27215-3361 = For inquiries, the physician may contact Branch: [iIIENIEEIS ab: SIENA Dir: Araceli B Reyes, MD Date Issued: 09/20/18 0832 ET FINAL REPORT Page 6 of 6 This docurment contains private and confidential health information protected by state and federal law. © 1995-2018 Laboratory Corporation of America® Holdings If you have received this document in error, please call nH All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299806

--=PAGE_BREAK=--

6972172618 16:18 Fron: Qi Woodson C. Merrell M Webfax Page: 8713 boratory Corporation of America Special Chemistry Department Raritan New Jersey erum Protein Electrophoresis Serum Proteins PE Gel T44577 Sample 32 09/17/2018 15:43:01:31 Accession Number 257480237106 Physician ID Patient Name EPSTEIN, JEFFREY Account Address 1 Total Protein 67 Account Address 2 44 E 67th St Patient ID Account Address 3 New York, NY 10065 Birthdate 1/20/1953 Account No./Name 31143082-Woodson Merrell OUP OY UO 257480237106 ii bee o tO ia ae il Frection _%& E) [Ra Abumin 60.3 4.0 2.9 to 4.4 Alpha-1 2.0 0.1 0.0 to 0.4 Alpha-2 11.7 0.8 0.4 to 1.0 Beta 13.3 0.9 0.7 to 1.3 Gamma 12.7 0.9 0.4 to 1.98 Total 6.7 6.0 to 8.5 The SPE pattem appears essentially unremarkable, Evidence of monoclonal protein is not apparent. EFTA00299807

--=PAGE_BREAK=--

69721726818 16:18 From: QS Woodson C. Merrell NM Vebfax Page: 9713 LabCorp Patient Report Specimen ID: 257-480-2230-0 Acct #: 31143092 Phone: NIM Rte: 68 Control ID: F4931143092 Woodson Merrell EPSTEIN, JEFFREY 44 E67th St 9E 71ST ST New York NY 10065 NEW YORK NY 10021 ee eee ee Patient Details Specimen Details Physician Details DOB:01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRELL Age(y/m/d): 0685/07/25 Date received: 09/15/2018 Referring: Gender: M SSN: Date entered: 09/15/2018 ID: Patient iD: JE012053 Date reported: 09/19/2018 0610 ET NPI: 1023153509 Ordered Items Vitamin 86, Plasma REFERENCE IN s RESULT Vitamin B6, Plasma Vitamin B6 7.2 ug/L 5.3 - 46.7 01 Disclaimer: ol This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration. 01 ~BN LabCorp Burlington Dir: William F Hancock, MD . ___1447 York Court. Burlington, NC 27215-3361 _ _ “For inquiries, the physician may contact Branch: Lab: Date Issued: 09/21/18 0838 ET FINAL REPORT Page 1 of 1 This document contains private and conficlential health information protected by state and federal law. © 1995-2018 Laboratory Corporation of America® Holdings if you have received this document in error, please a All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299808

--=PAGE_BREAK=--

69721726818 16:18 Pl 4 eas From: MN Woodson C. Merrell M Vebfax Acct #: 31143092 es WO OdSoOn Merrell EPSTEIN, JEFFREY Patient Details DOB: 01/20/1953 Agely/m/d): 065/07/25 Gender: M SSN: Patient ID. 44 E 67th St New York NY 10065 — Page: 10713 Lal orp TTY Specimen ID; 257-480-2232-0 Control !D; F5A31143092 Rte: 68 eben il Specimen Details Physician Details Date collected: 09/14/2018 1255 Local Ordering: Date received: 09/15/2018 Referring: Dateentered: 09/15/2018 ID: MERRELL Date reported: uy/ 10/2018 UBUY EI NPI: Ordered items Ca+PTH Intact Calcium PTH, Intact Intact PTH General Comments & Additional Information Total Volume: Not Provided Ca+PTH Intact Fasting: No 9.5 mg/dL Specimen received hemolyzed. Clinical correlation indicated. 71) High pg/mL “<4 - Interpretation Intact PTH (pg/mL) Normal 15 - 65 Primary Hyperparathyroidism >65 Secondary Hyperparathyroidism >65 Non-Parathyroid Hypercalcemia <65 Hypoparathyroidism <15 Non-Parathyroid Hypocalcemia 15 - 65 8.6 - 10.2 15 - 65 Calcium (mg/dL) 8.6 - 10. >10. <10. >10. < 8. < 8. HAVWNNL [ 07 RN LabCorp Raritan 69 First Avenue, Raritan, NJ 08869-1800 For inquiries, the physician may contact Branch; Dir; Araceli B Reyes, MD STEEN ES A TT A A AN RO TR TET FINAL REPORT Date Issued: 09/17/13 0916 ET Page | of 1 This document contains privete end confidential health information ‘a by state and federal law. © 1995-2018 Laboratory Corporation of America® Holdings If you have received this document in error, please call All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299809

--=PAGE_BREAK=--

6972172618 16:18 From: gies Yoodson C. Merrell M Webfax Page: 11713 LabCorp eae rg Specimen 1D: 257-480-2715-0 Acct #: 31143092 Phone: Rte: 68 Controt 1D: END31143092 Woodson Merrell EPSTEIN, JEFFREY A4E 67th St 9E71ST ST New York NY 10065 NEW YORK NY 10021 lhe er hl hee el ill Patient Details Specimen Details Physician Details DOB: 01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRELL Age(y/m/d): 065/07/25 Date received: (09/15/2018 Referring: Gender: M SSN: Date entered: 09/15/2018 1D: Patient ID: Date reported: 09/18/2018 0610 ET NPI; 1023153509 General Comments & Additional Information Total Volume: Not Provided Fasting: No Ordered Items Chiamycia/GC Amplification; Panel 083935; HCV Ab w/Rfix to Verification; RPR, Rfx Qn RPR/Confirm TP RESULT FLAG UNITS REFERENCE INTERVAL Chlamydia/GC Amplification Chlamydia trachomatis, NAA Negative Negative 01 Neisseria gonorrhoeae, NAA Negative Negative 01 Panel 083935 HIV Screen 4th Generation wRfx Non Reactive Non Reactive 61 HCV Ab w/REflx to Verification HCV Ab <0.1 s/co ratio 0.0 - 0.9 01 Comment : 01 Non reactive HCV antibody screen is consistent with no HCV infection, unless recent infection is suspected or other evidence exists to indicate HCV infection. RPR, Rfx Qn RPR/Confirm TP RPR Non Reactive Non Reactive 01 07 =RN LabCorp Rantan Dir: Araceli B Reyes, MD | — __69 First Avenue, Raritan, NJ 08869-1800 _ a Fe gies, he physi may conta Brac A > eA EIN aE SST OAS RA USSG POE A sr NA ns ON NT Date Issued: 09/18/18 1053 ET FINAL REPORT Page 1 of 1 This document contains private and confidential health information protected by state and federal law. © 1995-2018 Laboratory Corporation of America® Holdings if you have received this document in error, please le All Rights Reserved - Enterprise Report Version: 100 EFTA00299810

--=PAGE_BREAK=--

6972172618 16:18 From: ee ooson C. Merrell M Webfax Page: 12713 LabCorp [a TS Specimen ID: 257-480-2542-0 Acct #: 31143092 Phone: Rte: 68 Control iD: F5C3 1143092 Woodson Merrell EPSTEIN, JEFFREY 44E 67th St 9E7ISTST New York NY 10065 NEW YORK NY 10021 ee eh eae ehh Patient Details Specimen Details Physician Details DOB: 01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRELL Agely/m/d): 065/07/25 Date received: 09/15/2018 Referring: Gender: M SSN: Date entered: 09/15/2018 ID: MERRELL Patient ID: Date reported: 09/18/2018 0823 ET NPI: 1023153509 General Comments & Additional Information Total Volume: Not Provided Fasting: No Ordered Items Zinc, Whole Blood RESULT AC UNITS REFERENCE IN Zinc, Whole Blood 749 ug/dL 440 - 860 01 OT BN CabCorp Burlington a Dir: William F Hancock MD —sts—“‘_™SCS~S ee 1447 York Court, Burlington, NC 27215-3364 For inquiries, the physician may contact Branch: | Lab: Hin Date Issued: 09/18/18 1053 ET FINAL REPORT Page | of t This document contains private and confidential health informat otected by state and federal law. ® 1995-2018 Laboratory Corporation of America® Holdings Hf you have received this document in error, please call a All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299811

--=PAGE_BREAK=--

6972172618 16:18 Fron: ieee Woodson C. Merrell M Webfax Page: 13713 LabCorp eae nee rms Specimen ID: 257-480-2300-0 Acct #: 31143092 Phone: Rte: 68 Controt ID: 25648023000 Woodson Merrell EPSTEIN, JEFFREY 44. 67th St 9 EAST 71 STREET New York NY 10065 NYCNY 10021 eel eh heel ell Patient Details Specimen Details Physician Details DOB: 01/20/1953 Date collected: 09/14/2018 1255 Local Ordering: W MERRELL Agety/m/d): 065/07/25 Date received; 09/15/2018 Referring: Gender: M SSN: Date entered: 09/15/2018 ID: MERRELL Patient ID: Date reported: 09/19/2018 1011 ET NPE 1023153509 _ Ordered Items Heavy Metals Profile il, Blood RESULT FLAG UNITS REFERENCE INTERVAL Heavy Metals Profile II, Blood Lead, Blood 1 ug/dL 0-4 01 Blood Lead Collection Method: Venous Testing performed by Inductively coupled plasma/Mass Spectrometry. Environmental Exposure: WHO Recommendation <20 Occupational Exposure: OSHA Lead Std 40 BEI 30 Detection Limit = 1 Arsenic, Blood 8 ug/L 2 - 23 01 Detection Limit = 1 Mercury, Blood 2.1 ug/L 0.0 - 14.9 o1 Environmental Exposure: <15.0 Occupational Exposure: BEI - Inorganic Mercury: 15.0 Detection Limit = 1.0 Cadmium, Blood None Detected ug/L 0.0 - 1.2 o1 Environmental Exposure: Nonsmokers 0.3 - 1.2 Smokers 0.6 - 3.9 Occupational Exposure: OSHA Cadmium Std 5.0 BEI 5.0 Detection Limit = 0.5 [07 8N LabCorp Burlington Oir: William F Hancock, MD L. 1447 York Court, Burlington, NC 27215-3361 _ - For inquiries, the physician may contact conc) Date Issued: 09/21/18 0838 ET FINAL REPORT Page lof 1 This document contains private and confidential health information fected by state and federal law. © 1995-2018 Laboratory Corporation of America® Holdings # you have received this document in error, please i All Rights Reserved - Enterprise Report Version: 1.00 EFTA00299812